New Zealand markets open in 3 hours 23 minutes

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
1.0700-0.0400 (-3.60%)
As of 11:48AM EST. Market open.

Spruce Biosciences, Inc.

2001 Junipero Serra Boulevard
Suite 640
Daly City, CA 94014
United States
415 655 4168

Full-time employees22

Key executives

NameTitlePayExercisedYear born
Mr. Michael G. GreyExec. Chairman65kN/A1953
Mr. Samir M. Gharib CPA, CPA, M.B.A.Pres & CFO480kN/A1982
Dr. Javier Szwarcberg M.D., M.P.H.CEO & DirectorN/AN/A1970
Dr. Ralph William Charlton III, M.D.Chief Medical OfficerN/AN/A1970
Dr. Libbie Mansell M.B.A., Ph.D.Chief Regulatory & Quality OfficerN/AN/AN/A
Ms. P. J. RamtinSr. VP of Bus. OperationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Corporate governance

Spruce Biosciences, Inc.’s ISS governance QualityScore as of 1 December 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.